How Long Does Skyrizi Take to Work: What to Expect

Skyrizi (risankizumab) typically begins showing measurable results within the first four to sixteen weeks, though the exact timeline depends on which condition you’re being treated for. People with plaque psoriasis often see significant skin clearing by week 16, while those with Crohn’s disease may notice symptom relief as early as four weeks into treatment. The drug reaches its full steady-state levels in the body around week 16, which is why that timepoint features so prominently in clinical trials across all of its approved conditions.

Plaque Psoriasis: The Best-Studied Timeline

Psoriasis is where Skyrizi has the deepest body of evidence, and the results at the 16-week mark are striking. In the pivotal phase III trials, roughly 72 to 75 percent of patients receiving Skyrizi achieved at least a 90 percent improvement in their Psoriasis Area and Severity Index score by week 16.¹ That compared to just 2 to 5 percent of patients on placebo, and around 42 to 48 percent of those on ustekinumab, an older biologic targeting a related pathway. Those same trials showed Skyrizi outperforming adalimumab as well.²

That said, “week 16” is the primary endpoint researchers measured, not the moment the drug first kicks in. Many patients begin to see clearing earlier. The drug’s mechanism starts working shortly after the first injection, and visible improvements in redness, scaling, and thickness build progressively through those early weeks. If you’re four weeks in and feel like nothing is happening, that’s not unusual and doesn’t mean the drug won’t work for you. The clinical data show responses continue to build well beyond week 16.

Crohn’s Disease: Earlier Signs, Slower Full Remission

For Crohn’s disease, the timeline looks different because the drug is delivered intravenously during the induction phase rather than by the subcutaneous injections used in psoriasis. Real-world data from the STAR trial showed that over half of patients had a clinical response by week 4, and that number climbed to about 76 percent by week 8 and roughly 92 percent by week 12.³ So symptom improvement often comes fairly fast.

Full remission is another story. Clinical remission rates were about 12 percent at week 4, 22 percent at week 8, and 43 percent by week 12 in the same study.³ Transmural healing, where improvement extends through the full thickness of the intestinal wall rather than just the surface, was observed in about 16 percent of patients at week 12. The gap between feeling better and achieving deep healing matters in Crohn’s. You might notice reduced cramping and fewer urgent trips to the bathroom relatively soon, but the inflammatory damage inside the gut takes longer to resolve. Your gastroenterologist will likely schedule endoscopy or imaging down the line to check how the bowel itself is healing, separate from how you feel day to day.

Psoriatic Arthritis: Joint Relief Takes a Full Four Months

If you’re taking Skyrizi for psoriatic arthritis, expect a somewhat slower trajectory than with skin psoriasis alone. In a phase 2 trial, about 60 percent of patients on Skyrizi achieved at least a 20 percent improvement in their joint symptoms by week 16, compared with about 36 percent on placebo.⁴ More ambitious improvements, like a 50 or 70 percent reduction in joint disease activity, were less consistently reached at that early timepoint.

Quality-of-life measures tell a complementary story. By week 24, patients on Skyrizi reported meaningfully less fatigue and pain compared to placebo. Pain scores dropped by about 11 points more than placebo on a 100-point scale, and fatigue improved as well.⁵ Work productivity also improved. Joints are simply slower to respond than skin, partly because the inflammatory damage to joint tissue involves different cell populations and structural changes that take longer to reverse.

Ulcerative Colitis: The Newest Indication

Skyrizi’s approval for ulcerative colitis is more recent than its other indications, and the published evidence is still catching up. Expert evaluations describe it as effective for both inducing and maintaining remission in moderate-to-severe UC, including in patients who have already failed other treatments.⁶ The dosing schedule mirrors what’s used in Crohn’s: higher-dose intravenous infusions during the induction phase, followed by subcutaneous maintenance injections. If you’re starting Skyrizi for UC, the general expectation is similar to Crohn’s, with symptom improvement potentially beginning within the first few weeks and deeper mucosal healing building over months.

How Skyrizi Works and Why Results Build Gradually

Skyrizi targets a specific protein called IL-23 by binding to one of its components and preventing it from activating inflammatory pathways downstream.⁷ IL-23 doesn’t cause inflammation directly. Instead, it drives immune cells to produce other inflammatory molecules that do the actual damage to skin, joints, or gut lining. When you block IL-23, those downstream inflammatory signals don’t shut off instantly; they taper as the immune cells that were already activated run their course and aren’t replaced by newly activated ones.

This is why you don’t feel better the day after your first injection. The drug needs time to accumulate in your body and to suppress the cycle of inflammation. Steady-state blood levels of Skyrizi are reached around week 16.⁸ Before that, the drug is still building to its full therapeutic concentration. Once it reaches steady state, you’re getting the full benefit of each dose, and the benefits tend to plateau or continue slowly improving rather than declining.

What Happens After the First Year

One of the most reassuring findings about Skyrizi is how durable its effects are over time. In the LIMMitless long-term extension trial for psoriasis, efficacy was maintained through 304 weeks of continuous treatment, which works out to nearly six years. Over 83 percent of patients maintained at least 90 percent skin clearance, and more than half achieved complete clearance throughout that period.⁹ The average improvement from baseline was 95 percent or better from week 28 all the way through the end of the study.

This durability held across different patient groups regardless of age, sex, body weight, or whether they also had psoriatic arthritis. Patients with nail psoriasis, scalp psoriasis, or palmoplantar psoriasis all showed substantial improvement in those specific areas through 256 weeks, with nearly 45 percent of patients who had all three manifestations achieving complete clearance of all of them.¹⁰ Nail psoriasis, which is notoriously slow to respond to treatment because nails grow so slowly, improved by over 81 percent on average. Scalp psoriasis improved by over 94 percent. These are numbers that build over months and years, not weeks, so patience is warranted if you have these harder-to-treat areas.

Real-World Results Versus Clinical Trials

Clinical trials recruit carefully selected patients and monitor them closely, so there’s always a question of whether real-world results hold up. A three-year Italian multicenter study found that real-world effectiveness was comparable to, and in some cases slightly higher than, what the phase III trials reported. At one year, PASI 90 and PASI 100 rates matched or exceeded the UltIMMa trial figures, and improvement continued accumulating over the full three years of follow-up.¹¹

There’s an important nuance here. The real-world population had a higher proportion of bio-experienced patients, meaning people who had already tried and failed other biologics, including anti-IL-17 drugs that were underrepresented in the original trials.¹¹ The fact that results were still strong in this harder-to-treat group is encouraging. If you’ve been on other biologics before and they stopped working or never fully worked, that history doesn’t appear to blunt Skyrizi’s effectiveness to the extent it might with some other drug classes. Registry data from the UK has found that prior biologic exposure can reduce how long patients stay on a biologic, but this effect was more pronounced for IL-17 inhibitors than for IL-23 inhibitors like Skyrizi.¹²

When to Worry That It Is Not Working

The temptation is to judge the drug too early. Four weeks with minimal visible improvement, especially for psoriasis, is no reason to panic. The drug is still building in your system, and the inflammatory cascade it targets doesn’t reverse overnight. Most dermatologists and gastroenterologists will wait until at least week 16 before making a definitive call about whether the drug is working. For Crohn’s disease, the induction period itself lasts 12 weeks with IV infusions, so the earliest meaningful assessment typically happens around that mark.

If you’ve hit the 16-week point and your symptoms haven’t budged at all, that’s a more meaningful signal. But “not fully clear” and “no improvement” are very different things. Partial responders at week 16 often continue to improve through weeks 24, 52, and beyond. The long-term data show that the trajectory keeps climbing for many patients. If there’s been some improvement but not as much as you’d hoped, your doctor may recommend continuing rather than switching, especially since the safety profile is favorable over extended treatment periods.

Side Effects and Their Timing

The most commonly reported side effects of Skyrizi, like upper respiratory infections and headaches, tend to cluster early in treatment rather than developing later. A pharmacovigilance analysis of the FDA’s adverse event database found that the median time to onset for reported adverse events was around 115 to 124 days, and the pattern showed what researchers describe as “early failure type” characteristics, meaning that adverse events gradually decreased over time rather than accumulating.¹³

In practical terms, if you’re going to have side effects, they’re more likely to show up in the first few months than to appear suddenly a year into treatment. This pattern is reassuring for long-term use. The six-year psoriasis extension trial didn’t reveal any new safety signals that weren’t already apparent in the first year.⁹ Injection site reactions, when they occur, are generally mild and become less noticeable as you get accustomed to the injections.

Factors That Can Speed Up or Slow Down Your Response

Not everyone responds at the same speed, and a few factors influence where you’ll fall on the timeline. Disease severity matters: someone with moderate psoriasis covering 10 percent of their body may clear faster than someone with severe disease covering 30 percent, simply because there’s less inflammation to resolve. Body weight plays a role in how quickly the drug reaches effective concentrations, though the long-term subgroup analyses found that outcomes ultimately evened out across weight categories.¹⁰

Whether you’ve used other biologics before can also affect things. Patients who have cycled through multiple treatments sometimes take longer to respond, though as the real-world data show, they often do get there. In psoriatic arthritis, baseline markers of inflammation like C-reactive protein may actually predict a better response. Research on biomarkers across multiple studies has found that higher baseline CRP levels were associated with better treatment outcomes, possibly because patients with more active inflammation have more room for the drug to make a measurable difference.¹⁴

Quality of Life Beyond the Clinical Measures

Clinical scores like PASI and ACR are what trials measure, but they’re abstractions of what you actually experience. The quality-of-life data add an important dimension. In psoriatic arthritis, patients on Skyrizi reported improvements not just in pain and fatigue but in their ability to work and go about daily activities by week 24.⁵ These aren’t trivial outcomes. Chronic fatigue from persistent inflammation can be as disabling as visible symptoms, and it often goes unacknowledged. The fact that fatigue scores improved meaningfully suggests the drug is reducing systemic inflammation, not just clearing visible plaques or calming joint swelling.

In psoriasis, real-world studies have confirmed that the quality-of-life improvements seen in trials translate to everyday practice. Patients report significant reductions in how much their disease interferes with work and daily life.¹⁵ Itch, which is one of the most bothersome symptoms for people with psoriasis and one of the first things patients want relief from, was assessed in a pediatric trial and showed improvement at weeks 16 and 52.¹⁶ Though that study was in younger patients, the itch pathway is the same in adults, and most dermatologists report that itch is among the first symptoms to improve.

Skyrizi Versus Other Biologics in Head-to-Head Comparisons

If you’re choosing between Skyrizi and another biologic, the comparative speed of onset is a natural question. In psoriasis trials, Skyrizi outperformed both ustekinumab and adalimumab at the week 16 primary endpoint, with a notably wider margin over ustekinumab.¹ For Crohn’s disease, a head-to-head trial called SEQUENCE compared Skyrizi against ustekinumab in patients who had already failed anti-TNF therapy, with clinical remission at week 24 and endoscopic remission at week 48 as primary endpoints.¹⁷

These comparisons help frame expectations. Skyrizi’s onset isn’t dramatically faster than other modern biologics, but the depth of response at each timepoint tends to be higher. That’s a subtle but important distinction: you may not feel the difference at week 4, but by week 16 or 24, you’re more likely to have reached a higher level of clearance or remission with Skyrizi than with some older agents. The convenience factor also matters. After the induction period for Crohn’s or UC, the maintenance dose is a subcutaneous injection every eight weeks, which is less burdensome than drugs requiring more frequent dosing.

The Pediatric Picture

Skyrizi has been studied in children and adolescents with psoriasis, and the trajectory appears broadly similar to adults. In the OptIMMize-1 trial, pediatric patients showed improvements in both skin clearance and quality of life at weeks 16 and 52.¹⁶ The evidence base is thinner than for adults, but the week-16 response pattern mirrors what’s seen in adult trials. For parents managing a child’s psoriasis, the same general advice applies: don’t expect overnight results, give the drug at least 16 weeks, and look for gradual improvement in itch and visible plaques as early signals that the drug is working.

1
PubMed. Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis
2
PubMed Central. Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
3
PubMed Central. Efficacy and safety of Risankizumab for moderate-to-severe Crohn’s disease: first Asian real-world data (STAR trial)
4
PubMed Central. Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial
5
PubMed Central. Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1
6
Taylor & Francis Online (Expert Opinion on Biological Therapy). An evaluation of risankizumab for the treatment of moderate-to-severe ulcerative colitis
7
PubMed Central. Risankizumab: Mechanism of action, clinical and translational science
8
The Nurse Practitioner. Drug updates and approvals: 2019 in review – Section: Pharmacokinetics
9
PubMed Central. Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results
10
PubMed. Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial)
11
PubMed Central. Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study—IL PSO (ITALIAN LANDSCAPE PSORIASIS)
12
Wiley Online Library. Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register cohort study
13
Frontiers in Immunology. Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
14
PubMed Central. Biomarkers predictive of treatment response in psoriasis and psoriatic arthritis: a systematic review
15
PubMed Central. Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification
16
PubMed. Efficacy and Safety of Risankizumab in Paediatric Patients With Psoriasis in the OptIMMize-1 Phase III Study
17
SKYRIZI® (risankizumab-rzaa) HCP. How Long Does Skyrizi Take to Work: What to Expect – Section: H2H Endpoints